Three-Way Gene-Gene-Environmental Exposure Interaction Shown By NIEHS To Escalate Smoking-Related Bladder Cancer

August 27, 1998

Some smokers face a particularly high risk of bladder cancer because of variations in two genes that work together to escalate their already high risk, scientists at the National Institute of Environmental Health Sciences report.

The distinctive study may be the first to define a three-way gene-gene-environmental relationship to disease risk.

Both genes were previously known to have roles in metabolizing a chemical, arylamine, present in tobacco smoke and some occupations, such as those involving petroleum. But surprisingly, while a variation of one of the genes (NAT1) alone increased risk about twofold for smokers, variations of the second gene (NAT2) conveys no demonstrated risk unless the NAT1 variation is also present. When both variations are present, the risk for smokers is highest.

For example, someone who smokes 25 years and carries the at-risk copies of both genes has a tenfold higher risk of bladder cancer than someone who does not smoke.

The study, conducted among bladder cancer patients at the nearby Duke University Medical Center, Durham, N.C., and the University of North Carolina Hospitals, Chapel Hill, is reported in the journal Cancer Research, Vol. 58, issue 15. NIEHS is in Research Triangle Park, N.C.

"While everyone who smokes experiences higher risks of bladder cancer, this study suggests there may be small, genetically defined subgroups that suffer much higher risks than the general population," Dr. Taylor said. Though this is a preliminary study, the authors point out that people known to be in the higher risk subgroups could avoid smoking to decrease their risk of bladder cancer.

The authors are Jack A. Taylor, M.D., Ph.D., David M. Umbach, Ph.D., Douglas A. Bell, Ph.D. Elizabeth Stephens, and Trisha Castranio, all of NIEHS, and Cary Robertson, M.D. and David Paulson, M.D. of the department of surgery at Duke, and James Mohler, M.D. of the department of surgery at UNC.

NIH/National Institute of Environmental Health Sciences

Related Bladder Cancer Articles from Brightsurf:

Effectiveness of gemcitabine & daily RT for bladder preservation in muscle-invasive bladder cancer
Bladder preservation with trimodality therapy can be a safe and effective alternative to cystectomy for selected patients with muscle-invasive bladder cancer.

Anthrax may be the next tool in the fight against bladder cancer
Researchers at Purdue University have come up with a way to combine the anthrax toxin with a growth factor to kill bladder cancer cells and tumors.

Effectiveness of a new bladder cancer treatment demonstrated
Demonstrated the effectiveness of a drug for treating metastatic bladder cancer in patients who did not respond to the usual treatment.

Lifting the lid on bladder cancer support
Bladder cancer is a painful and sometimes life-threatening condition that patients can find difficult to talk about, with many becoming homebound as they cope with debilitating side effects such as incontinence.

How genomics profiling can help identify the best treatment for bladder cancer
A new computational tool -- a single-patient classifier -- effectively enables physicians to assign a bladder cancer subtype to an individual patient's cancer using that patient's genomic data.

Early menopause in smokers linked to bladder cancer
Research shows that experiencing menopause before the age of 45 is associated with a higher risk of bladder cancer.

Olfactory receptor as therapeutic target in bladder cancer
Researchers from Bochum have detected an olfactory receptor in the human bladder that might prove useful for bladder cancer therapy and diagnosis.

Bladder cancer model could pave the way for better drug efficacy studies
In the journal Cancer Research, UNC Lineberger Comprehensive Cancer Center researchers report they have developed a model of luminal bladder cancer, one of the two subtypes of advanced bladder cancer.

Genetic fixer-uppers may help predict bladder cancer prognosis
Mutations in genes that help repair damage to DNA may aid in predicting the prognosis of patients with bladder and other related cancers, according to researchers, who found that bladder cancer patients who had mutations in their ATM or RB1 genes -- proteins that help repair DNA damage when they're functioning normally -- tended not to live as long as patients without the mutations.

Simultaneous chemo and immunotherapy may be better for some with metastatic bladder cancer
Researchers from Mount Sinai and Sema4, a health information company and Mount Sinai venture, have discovered that giving metastatic bladder cancer patients simultaneous chemotherapy and immunotherapy is safe and that patients whose tumors have certain genetic mutations may respond particularly well to this combination approach, according to the results of a clinical trial published in European Urology.

Read More: Bladder Cancer News and Bladder Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to